Heather davis september 27 2011 ottawa canada
This presentation is the property of its rightful owner.
Sponsored Links
1 / 11

Heather Davis September 27, 2011 Ottawa, Canada PowerPoint PPT Presentation


  • 78 Views
  • Uploaded on
  • Presentation posted in: General

Biotech to Big Pharma Personal Experience. Heather Davis September 27, 2011 Ottawa, Canada. Coley’s founding technology: CpG oligonucleotides TLR9 agonists. Initial discovery was finding the molecular pattern in bacteria and DNA viruses that turns on the immune system shortly after infection

Download Presentation

Heather Davis September 27, 2011 Ottawa, Canada

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Heather davis september 27 2011 ottawa canada

Biotech to Big Pharma

Personal Experience

Heather Davis

September 27, 2011

Ottawa, Canada


Coley s founding technology cpg oligonucleotides tlr9 agonists

Coley’s founding technology:CpG oligonucleotides TLR9 agonists

  • Initial discovery was finding the molecular pattern in bacteria and DNA viruses that turns on the immune system shortly after infection

    • Specific DNA sequence known as “CpG motifs”

    • Activate through Toll-like receptor 9 found on certain immune cells

  • Coley discovered and developed synthetic CpG drugs

  • Platform technology with wide potential applications

    • Adjuvants for vaccines

      • Made current vaccines work better – can use lower doses (antigen sparing important during pandemic)

      • Allowed development of new types of therapeutic vaccines

    • Cancer immunotherapy

    • Treatment for asthma and allergy


Coley s technologies

Coley’s TLR Therapeutics™ Platform Progression

RNA AGONISTS

SMALL MOLECULES

TLR7, TLR8

ANTAGONISTS

TLR7, 8, 9

CpG

TLR9 AGONISTS

  • Cancers

  • Infectious Diseases

  • Autoimmune andInflammatory Disorders

    • Lupus

    • RA

  • Cancers

    • Solid

    • Hematologic

  • Asthma & Allergy

  • Vaccine Adjuvant

Coley’s Technologies

Original technology

Licensed from founders’

academic institutions

New technology

Developed in-house

Licensed from 3M after much of original technology licensed out


Coley s timeline

Coley’s Timeline

Co-founded by Art Krieg (U Iowa), Heather Davis (U Ottawa / OHRI) and Joachim Schorr (Qiagen)

  • Coley incorporated (1997 USA, 2001 Canada)

    • Incubated in Krieg & Davis academic labs until 2003

  • PRE-CLINICAL

  • CpG as vaccine adjuvant

    • Oncology immune therapy & therapeutic vaccines

      • Autoimmunity

  • CLINICAL

  • 1st three CpG clinical (vaccine) studies run from Ottawa

    • LICENSING DEAL

  • Cancer immune therapy clinical trials

    • Hepatitis C immune therapy

      • Lupus/RA immune therapy

Coley acquired by Pfizer

1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009

4


Licensing deals outcomes

Licensing Deals & Outcomes

Took to Phase 1 – no clinical activity since

In Phase 3 testing

Took to Phase 1 – cancelled license

No clinical testing

Emergent – completed Phase 1, ongoing activities

Took to Phase 1 – cancelled license

Phase 3 trial failed


How to succeed in biotech

How to succeed in biotech

  • Founder characteristics

  • Secure financing

  • Recruit senior management

  • Valuable technology, protected by IP

  • Luck & timing


Founder characteristics

Founder characteristics

  • Hard working, driven

  • Adaptable

    • Able to wear many hats

    • Successful transition from academia to corporate world requires thinking differently

  • Hard working


Securing financing

Securing financing

  • Coley had 1 year funding from founder

  • Initial venture funding was Swiss / German investors who had previously invested in corporate founder

  • Subsequent rounds introduced US investors

  • No Canadian VC’s ever participated

    • Too late

    • Expected too much control for their investment


Recruit senior management

Recruit senior management

  • Founders rarely make good senior managers

  • Coley benefitted for 3 years by using senior management of another company

  • Coley later hired own management team

    • Huge advantage having head office in Boston area

      • Candidates with senior drug development experience are relatively rare in Canad

    • Critical hires since each represents a single point of failure

    • Drug development complex and only learned through experience

      • Senior executives coming from Big Pharma sometimes couldn’t scale down to biotech appropriate activities


Valuable technology

Valuable technology

  • Technology must actually work

    • Positive clinical data trumps all

    • Selling technology on mouse data possible, but typically brings low value or back-loaded deals

  • Platform technologies have greater chance to succeed

  • Need to know when to let go

    • Unrealistic for biotech company to expect to develop pharmaceutical product to market

  • IP protection critical

    • Needs to be broad in scope and geography

    • IP protection costs escalate rapidly after provisional filing – difficult for academic unit to sustain until alternate financing secured


Wild cards

Wild cards

  • Luck

  • Timing


  • Login